Update Summary

Entity name

INOVIQ LTD

Announcement Type

Update to previous announcement

Date of this announcement

13/10/2025

Reason for update to a previous announcement

Confirming 5 November 2025 as the SPP issue date

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

INOVIQ LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type	**Registration Number**
ABN	58009070384

1.3 ASX issuer code

IIQ

1.4 The announcement is
Update/amendment to previous announcement

1.4a Reason for update to a previous announcement

Confirming 5 November 2025 as the SPP issue date

1.4b Date of previous announcement to this update

13/10/2025

1.5 Date of this announcement

13/10/2025

1.6 The Proposed issue is:
An offer of +securities under a +securities purchase plan
A placement or other type of issue

Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis?
No

Part 4B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

IIQ : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ASX +security code and description

IIQ : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

5,714,286

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?
No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?
No

Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?
Yes

Is the minimum acceptance unit based or dollar based?
Dollar based ($)

Please enter the minimum acceptance value

$ 1,000

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?
No

Describe all the applicable parcels available for this offer in number of securities or dollar value

Eligible shareholders may apply for shares under the offer in parcels valued at a minimum of $1,000 and thereafter in increments of $250 up to a maximum of $30,000.

Offer price details

Has the offer price been determined?
Yes

In what currency will the offer be made?	What is the offer price per +security?
AUD - Australian Dollar	AUD 0.35000

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?
Yes

Describe the scale back arrangements

The Plan aims to raise $2,000,000. The Board may:
(i) depending on the amounts subscribed by applicants under the SPP, exercise its absolute discretion to scale back applications in order to make the offer under the SPP more equitable and reflective of existing proportionate shareholdings; or
(ii) accept applications in excess of the $2,000,000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

13/10/2025

4C.2 +Record date

10/10/2025

4C.3 Date on which offer documents will be made available to investors

17/10/2025

4C.4 Offer open date

17/10/2025

4C.5 Offer closing date

29/10/2025

4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer

5/11/2025

Part 4D - Listing Rule requirements

4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?
Yes

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?
No

4E.2 Is the proposed offer to be underwritten?
No

4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?
No

4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

n/a

Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Proceeds from the placement and SPP will be primarily used to accelerate clinical validation and LDT commercialisation of the EXO-OC test and expedite preclinical development of INOVIQ's CAR-Exosome therapeutic program for solid tumours

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?
No

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

All countries other than Australia and New Zealand.

4F.3 URL on the entity's website where investors can download information about the proposed offer

https://www.inoviq.com/site/content/

4F.4 Any other information the entity wishes to provide about the proposed offer

No

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?
No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
Existing class

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ASX +security code and description

IIQ : ORDINARY FULLY PAID

Number of +securities proposed to be issued

27,142,860

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?
Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.35000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Part 7C - Timetable

7C.1 Proposed +issue date

17/10/2025

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

15,990,190

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?
Yes

7D.1c (i) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?

11,152,670

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?
No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?
No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?
Yes

7E.1a Who is the lead manager/broker?

PAC Partners Securities Pty Ltd appointed as the Lead Manager and Underwriter, with Arlington Group Asset Management Limited acting as advisor

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

A commission of 5% is payable to Arlington on the total proceeds raised from the cornerstone investor.
PAC will be paid a brokerage/underwriting fee of 5% of the total proceeds raised from all other investors in the placement.

7E.2 Is the proposed issue to be underwritten?
Yes

7E.2a Who are the underwriter(s)?

PAC Partners Securities Pty Ltd

7E.2b What is the extent of the underwriting (ie the amount or proportion of the proposed issue that is underwritten)?

$3m of the placement is underwritten

7E.2c What fee, commission or other consideration is payable to them for acting as underwriter(s)?

PAC will be paid a brokerage/ underwriting fee of 5% of the total proceeds raised from all other investors in the placement (other than the cornerstone investor).

7E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated.

The Underwriting Agreement includes customary termination events, including but not limited to:
- S&P ASX 200 Index fall of 15% or more (including hostilities in other countries*)
- Regulatory action by ASIC or another agency
- Unable to issue securities
- Failure to lodge an Appendix 2A
- Indictable offence by director or Snr Mgr
- Default or breach by the company*
- Incorrect representations*
- Contravention of the company's constitution or the Corporations Act*
- Event gives rise to a Material Adverse Effect*
- Misleading information or unapproved public statements*
- Change in Act or policy: not publicly disclosed or proposed as at the date of this Agreement that has a Material Adverse Effect on the Offer/Company*
- Company suspends payment of its debts generally*
- Insolvency*
- Litigation*
- Board/ senior management composition changes*
- Timetable delay*
- Breach of Material Contracts

*Events marked with an asterisk are subject to materiality

7E.3 Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed issue?
No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

N/A

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Proceeds from the placement and SPP will be primarily used to accelerate clinical validation and LDT commercialisation of the EXO-OC test and expedite preclinical development of INOVIQ's CAR-Exosome therapeutic program for solid tumours

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?
No

7F.2 Any other information the entity wishes to provide about the proposed issue

N/A

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)